Clinical Trial Update: Neoadjuvant Immunoradiotherapy With Evorpacept and Pembrolizumab in HPVOPC (Human Papilloma Virus Oropharynx Cancer) [Phase 2]

View source ↗

Summary

This Phase 2 study is evaluating neoadjuvant immunoradiotherapy combining evorpacept with pembrolizumab for HPV-positive oropharyngeal cancer and is currently r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hpv-positive Oropharyngeal Cancer

Drugs mentioned

• Evorpacept (ALX148)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: University of California, San Diego | Conditions: Oropharynx Cancer | Phase 2 | Status: RECRUITING